NASDAQ:XOMA

XOMA Stock Forecast, Price & News

$30.41
-0.40 (-1.30 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.00
$31.85
50-Day Range
$29.00
$38.99
52-Week Range
$15.48
$46.32
Volume24,188 shs
Average Volume43,756 shs
Market Capitalization$342.72 million
P/E Ratio160.05
Dividend YieldN/A
Beta0.96
30 days | 90 days | 365 days | Advanced Chart
Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.


XOMA logo

About XOMA

XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

601st out of 2,100 stocks

Pharmaceutical Preparations Industry

292nd out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











XOMA (NASDAQ:XOMA) Frequently Asked Questions

Is XOMA a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XOMA stock.
View analyst ratings for XOMA
or view top-rated stocks.

What stocks does MarketBeat like better than XOMA?

Wall Street analysts have given XOMA a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but XOMA wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is XOMA's next earnings date?

XOMA is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for XOMA
.

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.55. The biotechnology company had revenue of $0.38 million for the quarter, compared to analyst estimates of $1.23 million. XOMA had a trailing twelve-month return on equity of 5.63% and a net margin of 11.89%.
View XOMA's earnings history
.

How has XOMA's stock been impacted by Coronavirus?

XOMA's stock was trading at $19.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XOMA shares have increased by 55.9% and is now trading at $30.41.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for XOMA?

2 equities research analysts have issued 12-month price objectives for XOMA's stock. Their forecasts range from $36.00 to $56.00. On average, they anticipate XOMA's stock price to reach $46.00 in the next year. This suggests a possible upside of 51.3% from the stock's current price.
View analysts' price targets for XOMA
or view top-rated stocks among Wall Street analysts.

Who are XOMA's key executives?

XOMA's management team includes the following people:
  • Mr. James R. Neal, CEO & Director (Age 65, Pay $742.56k)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 47, Pay $495.38k)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 45)

What is John Varian's approval rating as XOMA's CEO?

11 employees have rated XOMA CEO John Varian on Glassdoor.com. John Varian has an approval rating of 73% among XOMA's employees.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

Who are XOMA's major shareholders?

XOMA's stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (31.33%), BlackRock Inc. (4.25%), Opaleye Management Inc. (3.88%), Geode Capital Management LLC (1.19%), Northern Trust Corp (0.88%) and Bank of New York Mellon Corp (0.55%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Matthew D Perry, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends for XOMA
.

Which institutional investors are selling XOMA stock?

XOMA stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Opaleye Management Inc., Northern Trust Corp, Geode Capital Management LLC, Morgan Stanley, EAM Investors LLC, Bank of New York Mellon Corp, and Nuveen Asset Management LLC. Company insiders that have sold XOMA company stock in the last year include Bvf Partners L P/Il, James R Neal, and Thomas M Burns.
View insider buying and selling activity for XOMA
or view top insider-selling stocks.

Which institutional investors are buying XOMA stock?

XOMA stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Virtu Financial LLC, Squarepoint Ops LLC, Barclays PLC, BlackRock Inc., Lazard Asset Management LLC, and Goldman Sachs Group Inc.. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal, Matthew D Perry, and Value Fund L P Biotechnology.
View insider buying and selling activity for XOMA
or or view top insider-buying stocks.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $30.41.

How much money does XOMA make?

XOMA has a market capitalization of $342.72 million and generates $29.39 million in revenue each year. The biotechnology company earns $13.30 million in net income (profit) each year or $0.78 on an earnings per share basis.

How many employees does XOMA have?

XOMA employs 10 workers across the globe.

What is XOMA's official website?

The official website for XOMA is www.xoma.com.

Where are XOMA's headquarters?

XOMA is headquartered at 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at (510) 204-7200 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.